Arthroscopy (also called arthroscopic surgery) is a minimally invasive surgical procedure in which an examination and sometimes treatment of damage of the interior of a joint is performed using an arthroscope, a type of endoscope that is inserted into the joint through a small incision. Arthroscopic procedures can be performed either to evaluate or to treat many orthopaedic conditions including torn floating cartilage, torn surface cartilage, ACL reconstruction, and trimming damaged cartilage.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum for the treatment of frozen shoulder syndrome (adhesive capsulitis).
The providers want accurate reimbursement, whereas the payers want efficient claims processing. The ever-changing CPT® code set doesn't make your job easy. According to the American Medical Association (AMA), there will be 335 total code changes in 2014, to include 175 new codes, 107 revised codes, and 47 deleted codes.
Mitek Sports Medicine*, a leader in orthopaedics sports medicine and a part of the DePuy Synthes Companies of Johnson & Johnson, announced it has added the RIGIDFIX® Curve Cross Pin System, the first of its kind, designed specifically for use with the anteromedial (AM) portal approach to enable a more anatomic ACL (anterior cruciate ligament) reconstruction.
Griffith University research projects have been awarded just over $6m in research funding by the prestigious National Health and Medical Research Council.
Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.
Omeros Corporation today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development.
Omeros Corporation today announced that it recently submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market OMS302 for use in patients undergoing intraocular lens replacement surgery in the European Union.
Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.
Omeros Corporation announced that the company recently submitted a New Drug Application to the U.S. Food and Drug Administration for approval of OMS302 for use in patients undergoing intraocular lens replacement surgery.
Ceterix Orthopaedics, Inc. today announced commercial availability of the company's NovoStitch suture passer in the United States. The company's device enables surgeons to place stitches in tight joint compartments, including those in knees, hips and shoulders, during minimally invasive arthroscopic surgical procedures.
Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.
Supplemental child restraints should be used by all children through age 8. When appropriate child safety restraint systems-based on a child's age and weight-are in use during motor vehicle crashes, the rates of mortality and serious injury significantly decrease. Most parents don't know that their older children-ages 4 to 8-should use additional measures to protect them from serious injury or death in case of a crash.
Omeros Corporation today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program.
Omeros Corporation today announced that its Investigational New Drug Application to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration.
SAGE today announces the launch of a new international open access journal, the Orthopaedic Journal of Sports Medicine. This journal was developed by the American Orthopaedic Society for Sports Medicine in collaboration with professional sports medicine organizations from around the world as a global, peer-reviewed open access journal that will publish content for both researchers and practitioners studying orthopeadic sports medicine, arthroscopy, and knee arthroplasty.
Omeros Corporation today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement.
Hospital for Special Surgery, the nation's top hospital for orthopedics, will host Current Concepts in Sports Medicine, an educational symposium to discuss how to identify, prevent and treat articular cartilage and hip/pelvis injuries, as well as injuries common to the throwing and multisport athlete.
MedShape, Inc., the industry leader in innovative shape memory orthopedic devices, today announced the company received U.S. Food and Drug Administration 510(k) clearance for its Eclipse Soft Tissue Anchor, a new shape memory fixation device designed to attach a tendon, ligament or soft tissue to bone.
Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.
Open access publisher BioMed Central is proud to announce the launch of BMC Sports Science, Medicine and Rehabilitation, another addition to the BMC-series portfolio.